OCULAR THERAPEUTIX, INC - Common Stock, $0.0001 par value per share (OCUL)

Historical Holders from Q3 2014 to Q3 2025

Symbol
OCUL on Nasdaq
CUSIP
67576A100
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
177M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
188M
Holdings value
$2.19B
% of all portfolios
0.021%
Grand Portfolio weight change
+0.001%
Number of holders
207
Number of buys
116
Number of sells
-75
Average Value change %
0%
Average buys %
+0.002%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of OCULAR THERAPEUTIX, INC - Common Stock, $0.0001 par value per share (OCUL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +22.5% $372M $142M 31.8M +62.1% FMR LLC Sep 30, 2025
Deep Track Capital, LP 6.18% -34.7% $153M -$27.6M 13.1M -15.3% Deep Track Capital, LP Sep 30, 2025
Venrock Healthcare Capital Partners III, L.P. 7.3% $151M 12.9M Venrock Healthcare Capital Partners III, L.P. Sep 30, 2025
BlackRock, Inc. 5.8% $119M 10.2M BlackRock, Inc. Sep 30, 2025
Opaleye Management Inc. 2.76% $30.4M 4.34M Opaleye Management Inc. Dec 31, 2024

Institutional Holders of OCULAR THERAPEUTIX, INC - Common Stock, $0.0001 par value per share (OCUL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 188M $2.19B +$369M $11.69 207
2025 Q2 156M $1.45B +$187M $9.28 182
2025 Q1 137M $1.01B +$22.1M $7.33 195
2024 Q4 134M $1.14B -$55.5M $8.54 177
2024 Q3 140M $1.22B +$26.5M $8.70 167
2024 Q2 137M $939M +$86.7M $6.84 147
2024 Q1 123M $1.12B +$444M $9.10 144
2023 Q4 286K $1.29M +$427K $4.46 3
2023 Q3 40.3M $126M -$13.9M $3.14 111
2023 Q2 43.2M $223M +$13.4M $5.16 130
2023 Q1 40.1M $212M +$6.22M $5.27 123
2022 Q4 39.4M $111M -$12M $2.81 107
2022 Q3 42.7M $177M -$4.08M $4.15 124
2022 Q2 44.2M $178M +$1.51M $4.02 118
2022 Q1 43.3M $215M +$8.63M $4.95 125
2021 Q4 35.8M $249M -$35.5M $6.97 132
2021 Q3 44.4M $444M -$46.2M $10.00 136
2021 Q2 48.2M $684M +$13.9M $14.18 143
2021 Q1 47.1M $774M -$64.9M $16.41 148
2020 Q4 50.2M $1.04B +$212M $20.70 143
2020 Q3 39.8M $303M +$7.13M $7.61 101
2020 Q2 38.7M $322M +$85.3M $8.33 103
2020 Q1 28.5M $141M +$17.9M $4.95 87
2019 Q4 22.4M $88.4M +$5.75M $3.95 74
2019 Q3 23.1M $70.2M +$1.03M $3.04 70
2019 Q2 19.4M $85.2M +$2.81M $4.40 60
2019 Q1 19.5M $77.3M +$2.21M $3.97 63
2018 Q4 18.7M $74.3M -$5.8M $3.98 63
2018 Q3 21.6M $149M -$1.51M $6.88 71
2018 Q2 21.8M $147M +$9.62M $6.75 65
2018 Q1 20.4M $133M +$45.7M $6.51 62
2017 Q4 12M $53.6M -$12M $4.45 65
2017 Q3 15.6M $96.5M -$1.1M $6.18 70
2017 Q2 15.3M $141M -$26.3M $9.27 70
2017 Q1 18.3M $170M +$20.3M $9.28 73
2016 Q4 17.4M $146M -$9.99M $8.37 76
2016 Q3 18.8M $129M -$2.94M $6.87 70
2016 Q2 19.4M $96.1M -$30.4M $4.95 72
2016 Q1 20.9M $201M -$1.63M $9.66 64
2015 Q4 21M $196M -$18.1M $9.37 70
2015 Q3 20M $282M +$49M $14.06 66
2015 Q2 16.1M $337M +$93M $21.03 70
2015 Q1 10.7M $449M +$241M $41.98 55
2014 Q4 5.01M $118M +$9.26M $23.52 36
2014 Q3 4.63M $69.3M +$69.3M $14.97 33